Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3652-3655

  Li, Yu ^a   Zhang, Hui bin ^a   Huang, Wen long ^a   Li, Yun man ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Multidrug resistance; P glycoprotein; Tetrahydroisoquinoline derivatives

Indexed keywords

6,7 DIMETHOXY 1 (3,4 DIMETHOXY)BENZYL 2 (N,N OCTYL N' CYANO)GUANYL 1,2,3,4 TETRAHYDROISOQUINOLINE; DOXORUBICIN; TETRAHYDROISOQUINOLINE DERIVATIVE; VERAPAMIL; VINCRISTINE;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; MULTIDRUG RESISTANCE; NONHUMAN;

AMIDINES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; MICE; MICE, NUDE; MYOCARDIAL CONTRACTION; NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TIME FACTORS; VERAPAMIL;

EID: 44649197081     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.082     Document Type: Article

References (28)

1. Biedler J.L., Chang T., Meyers M.B., Peterson F.H., and Spengler B.A. Cancer Treatment Rep 67 (1983) 859
2. Cole S.P.C., and Deeley R.G. Bioassays 20 (1998) 931
3. Dassow H., Lassner D., Remke H., and Preiss R. Int. J. Clin. Ther. 38 (2000) 209
4. Teodori E., Dei S., Scapecchi S., and Gualtieri F. Farmaco 57 (2002) 385
5. Tsuruo T., Iida H., and Tsukagoshi S. Cancer Res. 41 (1981) 1967
6. He L.W., Huang W.L., and Peng S.X. Prog. Pharma. Sci. 20 (1996) 193
7. He L.W., Huang W.L., Gao H., and Peng S.X. Chin. J. Med. Chem. 8 (1998) 196
8. He L.W., Huang W.L., and Peng S.X. J. China Pharm. Univ. 29 (1998) 157
9. He L.W., Huang W.L., Gao H., and Peng S.X. Acta Pharm. Sinica 33 (1998) 741
10. He L.W., Huang W.L., Shen Y.H., and Peng S.X. Acta Pharm. Sinica 33 (1998) 864
11. He L.W., Huang W.L., and Peng S.X. Chin. J. Med. Chem. 8 (1998) 265
12. He L.W., Huang W.L., and Peng S.X. Chin. J. Med. Chem. 9 (1999) 26
13. Huang, W. L.; Zhang, H. B.; Li, Y. M.; Zhou, J. P.; He, L. W.; Hu, Z.; CN Patent 03113262.6.
14. 4: C 68.94, H 8.10, N 10.72; found: C 68.58, H 8.13, N 10.65.
15. Mosmann T. J. Immunol. Methods 65 (1983) 55
16. 7/ml. When the tumors reached a mean diameter of 0.4-0.6 cm, the animals were randomized into groups of ten and treated with drugs in the intravenous injection three times a week. Control animals were treated with vehicle alone. Tumor weights were measured. The inhibition ratio (I%) of tumor growth was calculated using ((mean relative tumor weights of the treated group)/(the mean relative tumor weights of ADM group) - 1) × 100 (%).
17. emission = 535 nm) was measured in a microplate spectrofluorometer. Assays were performed in triplication. The inhibitory ratio (I%) was calculated using ((mean absolute fluorescence value of the treated group - the mean absolute fluorescence value of control)/the mean absolute fluorescence value of control) × 100 (%), where absolute fluorescence value for (fluorescence value of each well) - (the bases of fluorescence value of 96-well plate).
18. Schinkel A.H., Smit J.J.M., Tellingem O., Beijnen J.H., Wagenaar R., Demter L., Mol C.A.A.M., Valk M.A., Maandag-Robanu E.C., Riele H.P.J., Berns A.J.M., and Borst P. Cell 77 (1994) 491
19. Bowman P.D., and Betz A.L. In Vitro 34 (1998) 777
20. Zhang L., Liu X.D., and Xie L. Acta Pharmacol. Sinica 24 (2003) 903
21. Xu Y.G., and Liu Y. J. Chin. Microcirculation 2 (1997) 63
22. emission = 535 nm) was measured in a microplate spectrofluorometer. The content of protein was measured using the method of Coomassie brilliant blue for fluorescence intensity value. Assays were performed in duplicate, with at least three separate experiments.
23. emission = 535 nm) was measured in a microplate spectrofluorometer. The content of protein was measured using the method of Coomassie brilliant blue for fluorescence intensity value. Assays were performed in duplicate, with at least three separate experiments.
24. Seydel J.K., Velasco M.A., Coats E.A., Cordes H.P., Kunz B., and Wiese M. Quant. Struct.-Act. Relat. 11 (1992) 205
25. Pajeva I.K., Wiese M., Cordes H.P., and Seydel J.K. J. Cancer Res. Clin. Oncol. 122 (1996) 27
26. HH are fluorescence intensity value when excitation in horizontal direction. Assays were performed in duplicate, with at least three separate experiments.
27. 2 (5%). The isometric contractions of the aortic rings were measured with a force-displacement transducer. After 60 min of equilibration, the rings were exposed to 20 mM KCl or 80 mM KCl. When the tension had stabilized, the drugs were added to the bath at increasing concentrations until maximal relaxation. The relaxation response was expressed as the percentage of the contractile response to KCl.
28. SD rats (2.5-3.5 kg) were anesthetized with urethane (1.2 g/kg ip). The test compounds were dissolved in normal saline and administrated by femoral vein. Intravenous administration of aconitine nitrate (1 μg/0.2 ml/min) was kept constant velocity from femoral vein by peristaltic pump after 2 min.